TY - JOUR
T1 - Relapse rates and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapy
AU - Bots, Steven J.
AU - Kuin, Sabine
AU - Ponsioen, Cyriel Y.
AU - Gecse, Krisztina B.
AU - Duijvestein, Marjolijn
AU - D’Haens, Geert R.
AU - Löwenberg, Mark
PY - 2019
Y1 - 2019
N2 - Objective: We investigated relapse rates after anti-tumor necrosis factor (anti-TNF) withdrawal in inflammatory bowel disease (IBD) patients, response to restart of anti-TNF treatment and predictors for relapse. Methods: IBD patients in remission receiving infliximab or adalimumab treatment for ≥1 year who discontinued treatment were included. Relapse rates and predictors for relapse were studied using survival and Cox regression analysis. Results: In total, 101 patients were included (77 CD, 24 UC). A total of 56 patients (55%) experienced a relapse (CD 38, UC 18) with a median time to relapse of 32 and 18 months in CD and UC, respectively. Of patients that were retreated with the same anti-TNF agent, 84% responded. A trough serum concentration ≥2 µg/ml within 1 year prior to anti-TNF discontinuation was associated with a higher relapse rate in CD patients (HR 2.89; p =.018), which was more evident in patients requiring retreatment with biologicals, bowel-related surgery or experimental medication (HR: 4.18; p =.009). A young age (<17 years) at diagnosis was associated with a higher relapse rate (HR: 2.29; p =.040) and fecal calprotectin levels <25 µg/g with a lower relapse rate in CD patients (HR: 0.34; p =.041). Relapse rates, requiring treatment with biologicals or experimental medication, was lower in UC patients who continued immunosuppressive treatment (HR: 0.26; p =.042). Conclusions: Approximately 55% of patients relapsed after anti-TNF withdrawal with a median time to relapse of 32 and 18 months in CD and UC, respectively. Retreatment with the same anti-TNF was successful in 84% of patients.
AB - Objective: We investigated relapse rates after anti-tumor necrosis factor (anti-TNF) withdrawal in inflammatory bowel disease (IBD) patients, response to restart of anti-TNF treatment and predictors for relapse. Methods: IBD patients in remission receiving infliximab or adalimumab treatment for ≥1 year who discontinued treatment were included. Relapse rates and predictors for relapse were studied using survival and Cox regression analysis. Results: In total, 101 patients were included (77 CD, 24 UC). A total of 56 patients (55%) experienced a relapse (CD 38, UC 18) with a median time to relapse of 32 and 18 months in CD and UC, respectively. Of patients that were retreated with the same anti-TNF agent, 84% responded. A trough serum concentration ≥2 µg/ml within 1 year prior to anti-TNF discontinuation was associated with a higher relapse rate in CD patients (HR 2.89; p =.018), which was more evident in patients requiring retreatment with biologicals, bowel-related surgery or experimental medication (HR: 4.18; p =.009). A young age (<17 years) at diagnosis was associated with a higher relapse rate (HR: 2.29; p =.040) and fecal calprotectin levels <25 µg/g with a lower relapse rate in CD patients (HR: 0.34; p =.041). Relapse rates, requiring treatment with biologicals or experimental medication, was lower in UC patients who continued immunosuppressive treatment (HR: 0.26; p =.042). Conclusions: Approximately 55% of patients relapsed after anti-TNF withdrawal with a median time to relapse of 32 and 18 months in CD and UC, respectively. Retreatment with the same anti-TNF was successful in 84% of patients.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85063277813&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/30907185
U2 - https://doi.org/10.1080/00365521.2019.1582693
DO - https://doi.org/10.1080/00365521.2019.1582693
M3 - Article
C2 - 30907185
SN - 0036-5521
VL - 54
SP - 281
EP - 288
JO - Scandinavian journal of gastroenterology
JF - Scandinavian journal of gastroenterology
IS - 3
ER -